DGAP-News: MedX Limited: MedX Limited Projects 120% Sales Increase in Europe for 2011
(firmenpresse) - DGAP-News: MedX Limited / Key word(s): Miscellaneous
MedX Limited: MedX Limited Projects 120% Sales Increase in Europe for
2011
15.12.2010 / 10:00
---------------------------------------------------------------------
FOR IMMEDIATE RELEASE
MedX Limited Projects 120% Sales Increase in Europe for 2011
ORLANDO, Fl - PR NEWSWIRE - - MedX Limited (Frankfurt: 8MX), the
manufacturer and global distributor of MedX(R)-branded medical exercise and
fitness equipment, today announced a sales update. During 2010 the Company
sold exercise and medical machines to a diverse list of countries,
including Australia, Germany, Austria, India, Scotland, South Korea, Spain
and Switzerland. The MedX equipment will be used in various medical
rehabilitation and fitness facilities throughout the aforementioned
countries.
MedX projects sales in Europe to increase by 120% in 2011. In addition, the
Company anticipates increased sales of 80% in Asia and 60% in North and
South America.
MedX has been leveraging the well-trusted MedX brand throughout the United
States in growth niche markets within the health, fitness and wellness
industry. The sale of equipment to several nations worldwide is part of
its greater strategy to obtain a major presence in the international
market.
'MedX medical exercise equipment has long been recognized as the gold
standard in the industry, set apart from other strength training equipment
by our unique and scientific approach to exercise,' stated Larry Evans,
MedX President. 'We are very pleased to have this opportunity to further
establish our brand and expand our expertise into the global health and
fitness industry.'
Incorporated into every MedX product is decades of experience and millions
of dollars of independent, university-based research. Its products achieve
training efficiency through resistance curves matched to tested and proven
strength profiles.
About MedX Limited
MedX, Ltd. manufactures, markets and distributes exercise and medical
rehabilitation equipment to the medical and fitness markets. MedX is
credited for pioneering an entirely new category in the medical
rehabilitation and fitness equipment sector - Medical Exercise Technology -
which combines functional testing and resistance exercise; features
necessary to restore and enhance health by effectively treating chronic
neck and back pain. MedX holds more than 30 patents on its products, which
are among the most researched in the world. Since Arthur Jones sold
Nautilus in 1986 and devoted his career and money to cure back pain through
his creation of MedX, both the University of Florida School of Medicine and
the University of California in San Diego have been involved in countless
studies to validate the MedX products. In addition, more than 75
peer-reviewed medical journal articles have been published over the past 24
years confirming MedX's ability to significantly decrease chronic
spine-related pain issues, restore spinal function, improve quality of life
and independence, and decrease or eliminate the need for ongoing spinal
care or pain management even after multiple failed attempts at other forms
of treatment.
The proven success of MedX speaks for itself through a 'Who's Who' customer
base comprised of professional sports teams; colleges and universities -
both domestic and abroad; government agencies, including but not limited to
every branch of theU.S. Armed Forces, CIA, Department of Energy, Secret
Service, FBI and the Veterans Administration (numerous locations); Fortune
500 companies, such as General Motors and Tyson Foods; and hundreds of
medical rehabilitation hospitals and leading wellness centers throughout
North America and around the world.
Certain statements contained in this press release, which are not based on
historical facts, are forward-looking statements and are subject to
substantial uncertainties and risks, that may cause actual results to
materially differ from projections. Although the Company believes that its
expectations are reasonable assumptions within the bounds of its knowledge
of its businesses, expectations, representations and operations, there can
be no assurance that actual results will not differ materially from their
expectations. Important factors currently known to management that could
cause actual results to differ materially from those in forward-looking
statements include the Company's ability to execute properly its business
model, to raise additional capital to implement its continuing business
model, the ability to attract and retain personnel - including highly
qualified executives, management and operational personnel, ability to
negotiate favorable future debt facilities and capital raises, and the
inherent risk associated with a diversified business to achieve and
maintain positive cash flow and net profitability. In light of these risks
and uncertainties, there can be no assurance that the forward-looking
information contained in this press release will, in fact, occur.
End of Corporate News
15.12.2010 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
106458 15.12.2010
Datum: 15.12.2010 - 10:00 Uhr
Sprache: Deutsch
News-ID 32864
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 383 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: MedX Limited: MedX Limited Projects 120% Sales Increase in Europe for 2011"
steht unter der journalistisch-redaktionellen Verantwortung von
MedX Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
